PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 199 filers reported holding PDL BIOPHARMA INC in Q3 2016. The put-call ratio across all filers is 1.13 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $446,000 | -89.5% | 141,731 | -90.2% | 0.00% | -100.0% |
Q2 2020 | $4,228,000 | +561.7% | 1,452,856 | +540.8% | 0.00% | – |
Q1 2020 | $639,000 | -56.1% | 226,715 | -49.5% | 0.00% | – |
Q4 2019 | $1,456,000 | -30.4% | 448,646 | -53.7% | 0.00% | -100.0% |
Q3 2019 | $2,093,000 | +32.6% | 968,999 | +92.7% | 0.00% | – |
Q2 2019 | $1,579,000 | +107.8% | 502,797 | +146.3% | 0.00% | – |
Q1 2019 | $760,000 | -23.5% | 204,178 | -40.4% | 0.00% | – |
Q4 2018 | $993,000 | +124.2% | 342,531 | +103.2% | 0.00% | – |
Q3 2018 | $443,000 | -76.5% | 168,529 | -79.1% | 0.00% | -100.0% |
Q2 2018 | $1,885,000 | -34.2% | 805,613 | -17.3% | 0.00% | 0.0% |
Q1 2018 | $2,865,000 | -22.9% | 974,564 | -28.1% | 0.00% | 0.0% |
Q4 2017 | $3,714,000 | -15.6% | 1,355,629 | +4.5% | 0.00% | 0.0% |
Q3 2017 | $4,399,000 | +71.0% | 1,297,417 | +24.6% | 0.00% | 0.0% |
Q2 2017 | $2,572,000 | +15.4% | 1,041,308 | +6.0% | 0.00% | 0.0% |
Q1 2017 | $2,229,000 | -37.6% | 981,997 | -41.7% | 0.00% | 0.0% |
Q4 2016 | $3,571,000 | -62.1% | 1,684,060 | -40.1% | 0.00% | -66.7% |
Q3 2016 | $9,422,000 | +73.3% | 2,812,217 | +62.4% | 0.00% | +200.0% |
Q2 2016 | $5,436,000 | -12.5% | 1,731,406 | -7.2% | 0.00% | -50.0% |
Q1 2016 | $6,212,000 | -38.8% | 1,865,431 | -34.9% | 0.00% | -33.3% |
Q4 2015 | $10,146,000 | +260.3% | 2,866,159 | +412.0% | 0.00% | +200.0% |
Q3 2015 | $2,816,000 | -17.5% | 559,814 | +5.5% | 0.00% | 0.0% |
Q2 2015 | $3,412,000 | -50.8% | 530,649 | -46.2% | 0.00% | -66.7% |
Q1 2015 | $6,940,000 | +31.4% | 986,429 | +44.0% | 0.00% | +50.0% |
Q4 2014 | $5,280,000 | -6.2% | 684,808 | -9.1% | 0.00% | 0.0% |
Q3 2014 | $5,630,000 | +141.0% | 753,704 | +212.2% | 0.00% | +100.0% |
Q2 2014 | $2,336,000 | +46.9% | 241,416 | +26.2% | 0.00% | – |
Q1 2014 | $1,590,000 | -42.1% | 191,290 | -41.2% | 0.00% | -100.0% |
Q4 2013 | $2,746,000 | -56.3% | 325,303 | -58.8% | 0.00% | -50.0% |
Q3 2013 | $6,288,000 | -20.7% | 789,002 | -23.2% | 0.00% | -33.3% |
Q2 2013 | $7,927,000 | -22.4% | 1,026,738 | -29.3% | 0.00% | -25.0% |
Q4 2012 | $10,217,000 | +78.7% | 1,451,334 | +95.5% | 0.00% | +100.0% |
Q3 2012 | $5,716,000 | +109.7% | 742,359 | +80.5% | 0.00% | +100.0% |
Q2 2012 | $2,726,000 | +0.5% | 411,364 | -3.5% | 0.00% | 0.0% |
Q1 2012 | $2,713,000 | – | 426,476 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Virtus ETF Advisers LLC | 158,634 | $528,000 | 0.73% |
TFS CAPITAL LLC | 795,409 | $2,649,000 | 0.38% |
Dynamic Capital Management Ltd | 173,813 | $579,000 | 0.22% |
Acrospire Investment Management LLC | 91,141 | $303,000 | 0.21% |
GSA CAPITAL PARTNERS LLP | 905,024 | $3,014,000 | 0.19% |
RBF Capital, LLC | 273,976 | $912,000 | 0.18% |
Gotham Asset Management, LLC | 3,732,679 | $12,430,000 | 0.14% |
Advisors Asset Management, Inc. | 2,362,054 | $7,866,000 | 0.13% |
A.R.T. Advisors, LLC | 812,008 | $2,703,000 | 0.12% |
Bayesian Capital Management, LP | 37,200 | $124,000 | 0.12% |